Acadia Healthcare Company, Inc. reports developments tied to its national behavioral healthcare services business. The company owns and operates acute inpatient psychiatric facilities, specialty treatment facilities, comprehensive treatment centers, residential treatment centers and outpatient behavioral health clinics serving communities in the United States and Puerto Rico.
Recurring news for ACHC includes quarterly operating results, same-facility revenue, patient days, admissions, revenue per patient day, adjusted EBITDA guidance and performance across its facility categories. Company updates also cover facility network changes, investor conference participation, board composition, executive leadership transitions and operational initiatives in behavioral healthcare and recovery services.
Acadia Healthcare (NASDAQ: ACHC) will participate in three investor conferences in March 2026 with scheduled presentations and live webcasts. Presentations: Raymond James on March 2 at 11:35 a.m. ET, Leerink on March 9 at 3:40 p.m. ET, and Barclays on March 10 at 12:00 p.m. ET.
A live webcast and a replay available for 30 days will be accessible via the company website under the Investors section.
Acadia Healthcare (NASDAQ: ACHC) will release its fourth quarter and year-end 2025 results on Wednesday, February 25, 2026, before the market opens.
The company will host a conference call with institutional investors and analysts on February 25, 2026 at 9:00 a.m. ET, with a live webcast available on the company’s Investors page and a replay for 30 days.
Acadia Healthcare (NASDAQ: ACHC) appointed Debra K. Osteen as Chief Executive Officer and added her to the Board, effective immediately, with Chris Hunter departing the company and its Board. The Board said it will conduct a comprehensive search for a long-term successor while Osteen leads the company. The company reaffirms its full-year 2025 guidance, expecting revenue $3.28B–$3.30B, Adjusted EBITDA $601M–$611M, and adjusted EPS $1.94–$2.04. Management previously reiterated guidance at the J.P. Morgan Healthcare Conference on January 13, 2026. The company noted it cannot reconcile projected Adjusted EBITDA and adjusted EPS to GAAP due to unknown transaction-related expenses and their tax effects.
Acadia Healthcare (NASDAQ: ACHC) will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, January 12-15, 2026. The company’s presentation is scheduled for Tuesday, January 13, 2026 at 5:15 p.m. PT / 7:15 p.m. CT and will be webcast live on Acadia’s investor website.
A replay will be available on the company website for 30 days following the presentation. Investors can access the live webcast via the Investors section at www.acadiahealthcare.com.
Acadia Healthcare (NASDAQ: ACHC) updated its professional and general liability (PLGL) reserves after a third-party actuarial review, lowering 2025 guidance. The company now expects 2025 Adjusted EBITDA $601M–$611M (previously $650M–$660M) and Adjusted EPS $1.94–$2.04 (previously $2.35–$2.45), a reduction of $49M to EBITDA and $0.41 to EPS driven entirely by higher PLGL costs.
Key PLGL figures: projected 2025 PLGL expense ~$116M vs $54M in 2024 (+$62M); 168% increase in 2025 policy-year claim frequency; year-end 2025 net PLGL liability expected to be $145M–$165M (vs $78M at 12/31/2024); 2026 PLGL expense forecasted at $100M–$110M.
Acadia Healthcare (NASDAQ: ACHC) will participate in a fireside chat at the UBS Global Healthcare Conference in Palm Beach Gardens, Florida, running November 9–12, 2025.
The company’s presentation will be webcast live on Tuesday, November 11, 2025 at 1:45 p.m. Central / 2:45 p.m. Eastern and will be accessible via the Investors section of the company website. A replay will be available on the website for 30 days following the event.
Acadia Healthcare (NASDAQ: ACHC) reported Q3 2025 revenue of $851.6M, up 4.4% year-over-year, with same-facility revenue +3.7% and same-facility admissions +3.3%.
Adjusted EBITDA was $173.0M/b versus $194.3M a year earlier; adjusted EPS was $0.72 versus $0.91 prior-year. The company lowered full-year guidance to , Adjusted EBITDA $650–660M, and adjusted EPS $2.35–2.45.
Acadia added 429 beds in Q3 (908 YTD) and expects 945–1,076 bed additions for 2025. Management changes include CFO Todd Young joining Oct 27 and COO Dr. Nasser Khan resigning effective Nov 3. Cash was $118.7M with $786.7M available on the $1.0B revolver.
Acadia Healthcare (NASDAQ: ACHC) will release third quarter 2025 results on Wednesday, November 5, 2025 after market close. A conference call with institutional investors and analysts is scheduled for 9:00 a.m. ET on Thursday, November 6, 2025.
A live webcast will be available in the Investors section at www.acadiahealthcare.com and the webcast replay will remain accessible for 30 days.
Acadia (NASDAQ: ACHC) appointed Todd Young as Chief Financial Officer, effective October 27, 2025. Young brings roughly 25 years of financial and healthcare experience, most recently serving as CFO at Elanco where he helped build the finance organization after the company separated from Eli Lilly. He previously served as CFO of ACADIA Pharmaceuticals and holds a bachelor’s in economics and a law degree. Tim Sides, interim CFO since August 2025, will return to Senior Vice President, Operations Finance. Leadership says Young will focus on capital allocation, treasury, operational efficiency, and supporting disciplined growth in behavioral healthcare access and outcomes.
Khrom Capital Management LLC, owning 5.5% of Acadia Healthcare (NASDAQ: ACHC), has sent a critical letter to the company's Board of Directors demanding immediate strategic actions to address severe underperformance. The activist investor highlights ACHC's significant shareholder value destruction, with Total Shareholder Return (TSR) showing concerning metrics: -71.1% (1-year) and -70.7% (10-year).
The letter criticizes multiple strategic missteps, including the UK market exit, leadership changes, and aggressive capital expenditure amid DOJ investigations. Khrom Capital demands an immediate formal strategic review, including potential company sale, accelerated governance reforms, and Board restructuring, noting that current directors have served up to 20 years while collectively owning only 1.3% of company stock.